Urticarial hypersensitivity reaction caused by temozolomide.
Temozolomide is an oral alkylating agent approved for the treatment of glioblastoma and anaplastic astrocytoma, and is currently under clinical investigation for the treatment of brain metastases from a variety of cancers. Temozolomide is well tolerated, and the reported dermatologic side effects of this medication are limited. Here, the authors report the first case of an urticarial hypersensitivity reaction induced by temozolomide. As this drug will likely be increasingly utilized in the near future, it is important to be aware of its potential to cause adverse cutaneous manifestations.
Pothiawala
Salma
S
Department of Dermatology and Cutaneous Surgery, University of South Florida College of Medicine, Tampa, FL, USA.
Hsu
Mei-Yu
MY
Yang
Clarissa
C
Kesari
Santosh
S
Ibrahimi
Omar A
OA
D000328:Adult; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use; D018906:Antineoplastic Agents, Alkylating / Q000009:adverse effects* / Q000627:therapeutic use; D001254:Astrocytoma / Q000150:complications / Q000188:drug therapy; D001932:Brain Neoplasms / Q000150:complications / Q000188:drug therapy; D003606:Dacarbazine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D003875:Drug Eruptions / Q000473:pathology*; D004804:Eosinophils / Q000473:pathology; D005447:Fluocinonide / Q000008:administration & dosage / Q000627:therapeutic use; D006634:Histamine H1 Antagonists / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D008297:Male; D012867:Skin / Q000473:pathology; D000077204:Temozolomide; D014581:Urticaria / Q000139:chemically induced* / Q000473:pathology
D000893:Anti-Inflammatory Agents; D018906:Antineoplastic Agents, Alkylating; D006634:Histamine H1 Antagonists; D005447:Fluocinonide; D003606:Dacarbazine; D000077204:Temozolomide